Literature DB >> 26200968

GENOTYPE CHARACTERIZATION OF Leishmania (Viannia) braziliensis ISOLATED FROM HUMAN AND CANINE BIOPSIES WITH AMERICAN CUTANEOUS LEISHMANIASIS.

Lasaro Teixeira Ferreira1, Aparecida Helena de Souza Gomes2, Vera Lucia Pereira-Chioccola1.   

Abstract

INTRODUCTION: American tegumentary leishmaniasis (ATL) can be caused by Leishmania (Viannia) braziliensis complex. The evolution of ATL initially results in lesions and can develop into disseminated or diffuse forms. The genetic diversity of L. (V.) braziliensis in some endemic areas of Brazil has been poorly studied, such as in the state of São Paulo. This study analyzed the genetic diversity of L. (V.) braziliensis isolates collected from patients and dogs with LTA from the state of São Paulo.
METHODS: Leishmaniasis diagnosis was determined by PCR. The 132 biopsies were collected in different regions of Sao Paulo State, Brazil (36 municipalities). The genetic characterization of L. (V.) braziliensis isolates was tested by RFLP-PCR using DNA extracted from biopsies. The primer set amplified a specific region of Leishmania internal transcribed spacers of the ribosomal DNA locus.
RESULTS: Of the 132 samples, 52 (40%) were completely genotyped by RFLP-PCR (44 from human patients and eight from dogs). The results showed nine distinct patterns. The majority of the genotyped samples were from Sorocaba (30), and the others were distributed among 14 other municipalities. The first pattern was more frequent (29 samples), followed by pattern 2 (nine samples) and pattern 3 (three samples). Patterns 4, 6, 7, 8 and 9 were composed of two samples each and pattern 5 of one sample.
CONCLUSION: These results suggest that polymorphic strains of L. (V.) braziliensis circulate in the state of São Paulo. These data agree with studies from other regions of Brazil, showing great variability among the natural populations of endemic foci.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200968      PMCID: PMC4544252          DOI: 10.1590/S0036-46652015000300013

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


INTRODUCTION

The Leishmania genus causes leishmaniasis, which constitutes a variety of chronic diseases. There is a wide spectrum of clinical forms, including those affecting the skin, mucosa, or internal organs16 , 18. The subgenera LeishmaniaViannia is the causative agent of new-world cutaneous leishmaniasis, comprising the species L. (V.) braziliensis,L. (V.) panamensis and L. (V.) guyanesis, among others18 , 26. Infections by these species cause three clinical types of American tegumentary leishmaniasis (ATL): localized cutaneous, mucosal, and disseminated leishmaniasis. Cutaneous lesions are restricted to the entry site of the parasites, whereas the mucosal strain is defined by its spreading to the mucosal surfaces of the upper digestive and airway tracts. Disseminated leishmaniasis is characterized by large-scale spreading to distant cutaneous sites2 , 14 , 15 , 24. Despite the fact that cutaneous leishmaniasis is caused by at least seven different Leishmania species in Brazil, the vast majority of cases are caused by the L. (V.) braziliensissub-genera, which can be transmitted by different phlebotomine sandfly vectors via animal reservoirs across a wide geographic distribution1 , 7 , 16 , 18 , 28. ATL is widely distributed across the Americas. Between 2001 and 2011, around 270,500 cases were reported, with an average of 27,500 new cases/year. Around 3 - 5% of patients who develop cutaneous lesions are also susceptible to mucosal leishmaniasis23 , 30. In the state of São Paulo there are approximately 400 new cases per year. Another substantial problem is the urbanization of the infection. Autochthonous cases have been reported in urban areas. The incidence of peri-urban and urban cases has been increasing. Approximately 10% of the population living in endemic areas is at risk of acquiring the infection29. ATL is also considered one of the most common dermatological syndromes diagnosed in travelers (or tourists) who have visited endemic areas15. The life cycle of L. (V.) braziliensis includes different reservoirs, such as humans and wild and domestic mammals, as well as various vector species. Therefore, Leishmania strains can be maintained in both rural and urban settings, thereby affecting the epidemiology of the infection. Due to the proximity of dogs and humans, studies have shown the important role of domestic dogs in ATL19 , 21. Studies using molecular techniques to characterize L. (V.) braziliensis populations have contributed to a better understanding of the abilities of these parasites and their vectors in adapting to changes in their original forest habitats, and the consequent public health implications13. Despite the significance of ATL to the Brazilian public health system, the genetic diversity of L. (V.) braziliensis in some endemic areas of Brazil has been poorly researched, as in the state of São Paulo. Therefore, this study aims to analyze the genetic diversity of a L. (V.) braziliensis population collected from patients and dogs in the state of São Paulo with cutaneous lesions, avoiding in vitro cultivation. The reason for evaluating polymorphism in humans and dogs was due to the importance of both species within the parasite's life cycle. The results indicate a high variability in isolates collected in patients and dogs from the state of São Paulo. Additionally, this study has shown the possibility of performing genotyping directly on clinical samples without having to isolate the parasite.

MATERIAL AND METHODS

Human and dog samples: The selection of positive samples was made in biopsies received by an in-house Laboratory over a period of nine years (2003 - 2012). The biopsies were collected by medical or veterinary health services. The human or canine lesions were cleansed with antiseptics after the administration of a local anesthetic. The borders of the lesions were scraped or smears of material were obtained by a punch biopsy of the lesions and immediately added to tubes containing 1-2 mL of a sterile 0.85% NaCl and 200 µg/mL gentamicin solution, sent to the laboratory within 48 hours and promptly processed to confirm clinical diagnosis. All biopsies recorded were from patients with the cutaneous clinical form. Samples were tested by routine diagnosis, which included molecular and parasitological methods. The methodologies applied were PCR, using two different sets of primers, and a parasitological method (microscopic observation). These DNA samples were from patients and dogs living in 36 different municipalities and endemic areas for ATL in the state of São Paulo, Brazil (Alumínio, Aruja, Avaré, Bauru, Bragança Paulista, Cajamar, Campinas, Caraguatatuba, Cerquilho, Conhal, Cubatão, Guapiara, Guarulhos, Ibirá, Ilha Bela, Indaiatuba, Iperó, Iporanga, Itapera, Itupeva, Jaboticabal, Jundiaí, Mairiporã, Marília, Miracatu, Mirandópolis, Mogi Guaçu, Monte Mor, Pilar do Sul, Ribeira, Salto, São Paulo, Sorocaba, Suzano, Tatuí, Tietê). Epidemiological registers of the different Public Dermatology Clinics or Centers for Zoonosis Control were analyzed to determine the locality of the Leishmania infection of each patient (or dog). Ethical considerations: This study was performed according to the recommendations of the Human Ethics Committee (CONEP-IAL) and "Sociedade Brasileira de Ciência em Animais de Laboratório/Colégio Brasileiro de Experimentação Animal" (SBCAL/COBEA). Both Ethic Committees of Instituto Adolfo Lutz have approved of this study. For genotype standardization, the following WHO standard Leishmania strains were used: L. (V.) guyanensis (MHOM/BR/1975/M4147), L. (L.) amazonensis(IFLA/BR/1967/PH8), L. (L.) major (MHOM/SU/1973/5-ASKH), L. (L.) infantum (MHOM/BR/1974/PP75), and L. (V.) braziliensis(MHOM/BR/1975/M2903). The Leishmania strains were maintained by serial passages and grown at 24 ºC in M-199 medium, supplemented with 10% calf serum and 0.25% hemin25. In the log phase, 1 x 108parasites were harvested and washed twice in phosphate-buffered saline (pH 7.2) at 1,000g for 10 min. The parasite pellets were used for DNA extraction. L. (V.) braziliensis strain DNA also was used in reactions as a positive control. DNA purification: Before performing DNA extraction, clinical samples and WHO Leishmania reference strains were crushed and digested in a lysis buffer until tissue lysis was complete, (This-HCl, 10 mM, pH 8.0; EDTA 10mM; SDS, 0,5%; N-laurilsarcozil, 0.01%; proteinase K, 100 µg/mL) by incubation in water bath at 56 ºC. Then, DNA molecules were extracted by a QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's instructions. DNA concentration and purity was determined by the ratio of O. D. at 260 and 280 nm in a NanoDrop ND1000 (Thermo Scientific).

Routine Leishmania diagnosis

Parasitological diagnosis: Skin biopsy imprints were plated onto a glass slide, fixed with methanol and stained with Giemsa11. The presence of amastigotes was observed microscopically with an immersion objective (×1,000). PCR targets for The Leishmania genus was identified by a 120-bp PCR product, amplified from a conserved region of kDNA minicircles of Leishmaniaspp. , using the primer set 150/15223. L. (V.) braziliensis was identified by an amplified fragment of 146-149 bp from the multicopy spliced leader (SL) RNA gene using the primer set LU-5A/LB-3C, which amplifies a 146-149 bp sequence from the SL12 , 17. These tests were carried out under the same aforementioned conditions11 , 12. To check PCR inhibitors, canine and human samples were assayed using a reference gene, whose primer sets were GAPDH4F/GAPDH4R and β1-β2, respectively, in the same conditions as previously described3 , 11. After the thermal cycles, PCR products were electrophoresed in 2% agarose gel and stained with ethidium bromide. DNA fragments were made visible under UV illumination. Originally, 132 DNA extracts from biopsies, positive for L. (V.) braziliensis, were analyzed for genotype determination. PCR was used for diagnosis and genotyping directly from clinical DNA samples. Each test was performed by adding 5 µL from each DNA template and 25 pmol from each primer for a final volume of 25 µL. The amplifications were carried out with a kit purchased from Promega (Go Taq Green Master Mix). The PCR mix (12.5 μL) was composed of one unit of Taq DNA polymerase, 10 mM Tris-HCl, pH 8.5; 50 mM KCl; 1.5 mM MgCl2; and 200 mM of each dNTP. In genotype reactions the primer set used was IR1/IR2 (5'-GCTGTAGGTGAACCTGCAGCAGCTGGATCATT-3' and 5'-GCGGGTAGTCCTGCCAAACACTCAGGTCTG-3'), which amplified a 1-1.2-kb sequence from the ITS region between the small and large subunits of the rDNA locus in a temperature annealing at 56 ºC5. PCR-amplified products were digested with a HhaI restriction enzyme, which were separated by electrophoresis in an 8% polyacrylamide gel and stained with ethidium bromide. DNA fragments were made visible under UV illumination. The images from reactions for diagnosis and genotyping were analyzed by a MiniBIS Gel Imager and Documentation system (BioSystematica). The size of the fragments was based on a comparison with molecular-weight size markers. In genotyping reactions, the banding patterns were used to group the isolates into genotypes with the same banding pattern for the restriction enzyme. Quality assurance: Each DNA extraction batch included a DNA extraction from Leishmania -free eukaryotic samples as a negative control. In each reaction, a tube containing nuclease-free water and PCR mix was used as a blank control. Separate rooms were used for i. DNA extraction, ii. PCR mix and primer preparation, iii. the adding of DNA from clinical samples and positive control; and iv. post-PCR agarose-gel electrophoresis analysis. DNA samples were assayed in duplicate and at least twice.

RESULTS

The first experiments were conducted using the DNA extracted from WHO reference strains to establish the genotype by RFLP-PCR, using the primer set IR1/IR2 and additional treatment with HhaI enzymes.Figure 1 shows the restriction patterns of the six WHO reference strains. L. (V.) guyanensis and L. (V.) braziliensis showed the same restriction profile. On the other hand, L. (L.) amazonensis, L. (L.) major and L. (L.) infantum had specific restriction profiles.
Fig. 1

Restriction patterns of PCR products digested with HhaI in DNA extracted from standard Leishmania strains include the following: L. (V.) guyanensis (MHOM/BR/1975/ M4147) (1), L. (L.) amazonensis (IFLA/BR/1967/PH8) (2), L. (L.) major(MHOM/SU/1973/5- ASKH) (3), L. (L.) infantum (MHOM/BR/1974/PP75) (4), and L. (V.) braziliensis (MHOM/BR/1975/M2903) (5). Digested products were resolved in 2% agarose gel stained with ethidium bromide. MM, 50-bp ladder.

Next, genotype experiments were conducted on the 132 DNA samples taken from biopsies with a positive parasitological and molecular diagnosis. All samples also tested positive for L. (V.) braziliensis (in PCR), which was previously determined by the LU-5A/LB-3C primer set, whose products range in size from 146 to 149 bp9 , 12 , 17. According the epidemiological registers of the Public Dermatology Clinics and Centers for Zoonosis Control, all samples analyzed were from patients or dogs with an autochthonous Leishmania infection (in the same locality as the biopsy collection). Of the 132 DNA samples, only 52 (40%) were successfully genotyped, as 1 - 1.2 kb products were amplified by the IR1/IR2 primer set. The other 80 samples were not genotyped, as PCR products were not amplified by this primer set. As expected, no amplification was detected in DNA extracted from DNA as a negative control and PCR products were obtained for all positive controls. Table 1 shows the specification of the 52 genotyped samples in detail, which included the collection date of the biopsies (2003 - 2012), as well as the host (human or canine) and locality within the state of São Paulo. The 52 samples were distributed in nine distinct patterns, as shown in Figure 2.
Table 1

Clinical samples genotyped by RFLP-PCR in this study

Sample code-month/yearHostMunicipalitySample code-month/yearHostMunicipality
07-09/2003HumanSorocaba1063-07/2008HumanSorocaba
18-09/2003HumanSorocaba1153-11/2008HumanCampinas
20-09/2003CanineSorocaba1324-02/2009HumanSorocaba
26-10/2003CanineMarilia1622-08/2009HumanSorocaba
64-09/2004HumanSorocaba1758-02/2010HumanJundiai
65-09/2004HumanSorocaba1945-06/2010HumanJundiai
84-11/2004CanineIlha Bela1946-10/2010HumanJundiai
115-03/2005HumanSorocaba1985-11/2010HumanBauru
125-03/2005HumanSorocaba2001-12/2010HumanSorocaba
157-06/2005HumanItupeva2036-02/2011CanineIporanga
194-08/2005HumanSorocaba2037-02/2011CanineIporanga
253-11/2005HumanSorocaba2038-02/2011CanineIporanga
274-05/2006HumanMairiporã2072-04/2011HumanIperó
275-05/2006HumanCajamar2098-06/2011HumanSorocaba
279-05/2006HumanItapera2135-09/2011HumanSorocaba
281-05/2006HumanSorocaba2136-09/2011HumanSorocaba
282-05/2006HumanSorocaba2150-09/2011HumanSorocaba
288-06/2006HumanItupeva2151-09/2011HumanSorocaba
304-08/2006HumanSorocaba2152-09/2011HumanSorocaba
327-08/2006CanineAvaré2163-10/2011HumanSorocaba
354-10/2006HumanSorocaba2302-01/2012HumanSorocaba
504-09/2007HumanSorocaba2538-05/2012HumanSorocaba
560-12/2007HumanSorocaba2656-07/2012HumanRibeira
684-03/2008HumanSorocaba2657-07/2012HumanRibeira
829-05/2008HumanSorocaba2658-07/2012HumanRibeira
832-05/2008CanineCaraguatatuba2883-12/2012HumanIperó
Fig. 2

Amplified products (1-1.2 kb) of clinical samples of the ITS region between the small and large subunits of rDNA locus from L. (V.) braziliensis were digested with HhaI (RFLP patterns). Among the 52 clinical samples, nine restriction patterns were shown. Digested products were resolved in 8% polyacrylamide gels stained with ethidium bromide. MM, 50-bp ladder.

Pattern 1 was identical to those found in L. (V.) guyanensis and L. (V.) braziliensis WHO reference strains (Fig. 1). Furthermore, this L. (V.) braziliensispattern was the most common, since out of the 52 genotyped samples, 29 (56%) belonged to pattern 1 and were distributed across 11 different municipalities. Pattern 2 was recurrent in nine samples distributed across three municipalities. The other patterns (3 - 9) were uncommon and found in few samples: Pattern 3 (three municipalities), 4 (two municipalities), 5 (one municipality), 6 (one municipality), 7 (one municipality), 8 (two municipalities), 9 (two municipalities), respectively. The details and distribution of the clinical samples from the 44 human patients and eight dogs for each L. (V. ) braziliensis isolate are shown in Table 2 and Figure 3. The majority (30) of the samples were from Sorocaba. The others (22) were distributed across the other 14 municipalities.
Table 2

Distribution of the nine L. (V.) braziliensis profiles isolated from human and canine clinical samples in 15 municipalities of the state of São Paulo

L. (V.) braziliensis genotyping (n)Municipality (n=15)HumanCanine
Pattern 1 (29 samples)Bauru1-
Cajamar1-
Caraguatatuba-1
Iperó2-
Iporanga-2
Itapera1-
Itupeva2-
Jundiai2-
Mairiporã1-
Ribeira2-
Sorocaba131
Pattern 2 (9 samples)Jundiai1-
Ribeira1-
Sorocaba7-
Pattern 3 (3 samples)Avaré-1
Marilia-1
Sorocaba1-
Pattern 4 (2 samples)Campinas1-
Sorocaba1-
Pattern 5 (1 sample)Sorocaba1-
Pattern 6 (2 samples)Sorocaba2-
Pattern 7 (2 samples)Sorocaba2-
Pattern 8 (2 samples)Iporanga-1
Sorocaba1-
Pattern 9 (2 samples)Ilha Bela-1
Sorocaba1-
Total of samples 448
Fig. 3

Map of South America and Brazil (A) indicating the location of the state of São Paulo (A). Map of the state of São Paulo (B) indicating the municipalities studied and geographical distribution of the L. (V.) braziliensispatterns: 1 (red), 2 (yellow), 3 (green), 4 (blue), 5 (purple), 6 (orange), 7 (pink), 8 (light blue) and 9 (gray).

DISCUSSION

ATL has been growing worldwide in both incidence and range, principally due the increase in human migration. This mobility contributes to the emergence of leishmanial infection in low or non-endemic areas13. To prevent new cases in these areas, epidemiological strategies must be implemented, such as rapid diagnosis, treatment and vector control. The importance of the study of genetic variability of Leishmania is mainly due to its correlation with the epidemiological aspects of the disease, such as geographic location, clinical forms, virulence, pathogenicity, drug resistance and antigenic variation, among others6 , 13. Species belonging to the L. (V.) braziliensis sub-genera are highly prevalent in patients with ATL in Brazil. Other Brazilian studies have shown the genetic variability of these parasites, which would explain their adaptation to changes in diverse environmental conditions4 , 6. Thus, with such resilience, these parasites are more likely to infect multiple hosts. Although different genetic studies have analyzed L. (V.) braziliensis isolates from other Brazilian regions4 , 6 , 10 , 11 , 21 , 27, none have been conducted in the state of São Paulo. The idea of conducting this study in the state of São Paulo was motivated by the state's increase of ATL incidences for the last 20 years. Currently, 147 municipalities have already recorded transmission. Thus, in this study, biopsies from 24.5% of these municipalities (36) were investigated. However, due to the low sensitivity of the IR1/IR2 primer set, samples from only 15 municipalities were genotyped. One of the methods used to evaluate the genetic polymorphism of L. (V.) braziliensis isolates in different Brazilian regions is the analysis of RFLP in the internal transcribed spacers (ITS) of the ribosomal DNA (rDNA) locus. These studies have shown that molecular markers are suitable for population genetics and epidemiological studies4 , 5 , 6. Despite the low sensitivity of the IR1/IR2 primer set and that the clinical samples presented a low quantity of parasites in comparison with culture isolates, 40% (52/132) of them were genotyped. Similar data has previously shown20 the possibility of performing RFLP-PCR using small amounts of Leishmania DNA from host tissues. Consequently, it is possible to genotype Leishmania populations with the analysis of DNA extracted directly from clinical samples. This information is important, because in many laboratories there are no conditions in which to isolate and culture parasites from clinical samples20. Another interesting finding was the fact that DNA samples isolated 11 years ago (2003) were of good quality and could be used to genotype L. (V.) braziliensis isolates, as shown in Table 1. Results showed that L (V.) braziliensis seems to be a species with great genetic diversity, as nine different patterns were observed in 52 different DNA samples from 15 municipalities using PCR-RFLP. As shown in Figure 3, the different L (V.) braziliensispatterns were spread throughout the regions. This genetic variability has already been shown in other Brazilian studies4 , 10 , 11 , 21 , 27. Additionally, the parasite polymorphism was correlated with different clinical forms of the disease, effectiveness of treatment and cytokines expression10 , 21 , 27. According to other studies4 , 6 , 23 , 29, genotypic variations exhibited by L (V.) braziliensis could be explained by the adaption of parasites to changes in the transmission process, as originally, the biological cycle was restricted to forest environments. Similar to in other Brazilian regions, the gradual removal of vegetation has also occurred in São Paulo in recent years29. As a result, these parasites have adapted to infect a wider diversity of sand flies and reservoirs.
  27 in total

1.  Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil.

Authors:  Elisa Cupolillo; Lúcia Regina Brahim; Cristiane B Toaldo; Manoel Paes de Oliveira-Neto; Maria Edileuza Felinto de Brito; Aloisio Falqueto; Maricleide de Farias Naiff; Gabriel Grimaldi
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  An oligonucleotide probe derived from kDNA minirepeats is specific for Leishmania (Viannia).

Authors:  O Fernandes; M Bozza; J M Pascale; A B de Miranda; U G Lopes; W M Degrave
Journal:  Mem Inst Oswaldo Cruz       Date:  1996 May-Jun       Impact factor: 2.743

Review 3.  Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification.

Authors:  J A Rioux; G Lanotte; E Serres; F Pratlong; P Bastien; J Perieres
Journal:  Ann Parasitol Hum Comp       Date:  1990

4.  PCR identification of Leishmania in diagnosis and control of canine Leishmaniasis.

Authors:  Aparecida H S Gomes; Isabelle M R Ferreira; Maria L S R Lima; Elaine A Cunha; Andrea S Garcia; Maria F L Araújo; Vera L Pereira-Chioccola
Journal:  Vet Parasitol       Date:  2006-12-28       Impact factor: 2.738

Review 5.  Immune-clinical-pathologic spectrum of leishmaniasis.

Authors:  R D Azulay; D R Azulay Júnior
Journal:  Int J Dermatol       Date:  1995-05       Impact factor: 2.736

6.  In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR.

Authors:  Juliana Q Reimão; Fábio A Colombo; Vera L Pereira-Chioccola; André G Tempone
Journal:  Exp Parasitol       Date:  2011-02-24       Impact factor: 2.011

7.  Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis.

Authors:  A Schriefer; A L F Schriefer; A Góes-Neto; L H Guimarães; L P Carvalho; R P Almeida; P R Machado; H A Lessa; A Ribeiro de Jesus; L W Riley; E M Carvalho
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Genetic diversity in natural populations of New World Leishmania.

Authors:  E Cupolillo; H Momen; G Grimaldi
Journal:  Mem Inst Oswaldo Cruz       Date:  1998 Sep-Oct       Impact factor: 2.743

9.  [Leishmania (Viannia) braziliensis in naturally infected dogs].

Authors:  Maria de Fátima Madeira Md; Cláudia M Antunes Uchôa; Cristianni Antunes Leal; Roger M Macedo Silva; Rosemere Duarte; Ciléia M Magalhães; Cathia Maria Barrientos Serra
Journal:  Rev Soc Bras Med Trop       Date:  2003-10-21       Impact factor: 1.581

10.  Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis.

Authors:  E M Carvalho; A Barral; J M Costa; A Bittencourt; P Marsden
Journal:  Acta Trop       Date:  1994-04       Impact factor: 3.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.